Potential synergy of cerebrospinal fluid TREM2 and BDNF/TrkB pathways promote mild depressive symptoms in Alzheimer's disease through tau pathology

Background Early identification of Alzheimer's disease (AD) remains challenging. Mild depressive symptoms (MDSs) during the prodromal stage accelerate cognitive decline, but the underlying mechanisms remain unclear. Neuroinflammation and neurotrophic support are implicated in cognitive impairment, yet the interaction between triggering receptor expressed on myeloid cells 2 (TREM2)-mediated neuroimmune dysregulation and brain derived neurotrophic factor (BDNF)/tropomyosin receptor kinase B (TrkB) deficits has not been established. Objective This study aimed to investigate whether alterations in cerebrospinal fluid (CSF) TREM2/sTREM2 and BDNF/TrkB interact to affect cognition in patients with AD and MDSs and whether tau pathology mediates this relationship, using observational data from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Methods ADNI data collected from 2005 to 2013 included 653 eligible participants. CSF TREM2, sTREM2, BDNF, TrkB, Aβ 42 , pTau181, and tTau levels, neuropsychiatric measures, and cognitive scores were analyzed using analysis of covariance, stratified analyses, mediation analyses, and multivariable linear regression adjusted for age, sex, education, and APOE ε4 status. Results CSF BDNF, TREM2, and sTREM2 levels varied significantly with age. sTREM2 appeared protective in early but not late disease stages. Reduced BDNF/TrkB signaling was associated with MDSs and poorer memory and executive function. Mediation analyses indicated that MDS-related cognitive impairment was partly mediated by TREM2/sTREM2-associated neuroinflammation and BDNF/TrkB dysfunction, particularly with elevated tau pathology. Conclusions TREM2-mediated neuroimmune dysfunction and impaired BDNF/TrkB support may jointly exacerbate tau-related cognitive decline in preclinical AD with MDSs. This immune-neurotrophic interaction may promote dysfunctional microglial activation, excessive inflammation, and reduced clearance, offering a potential mechanism linking depressive symptoms to accelerated AD progression and informing early risk stratification and targeted intervention.

Authors

Institutions

Publication Details

Journal
Journal of Alzheimer s Disease
Published
2026-11-14
DOI
https://doi.org/10.1177/13872877261503497
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Potential synergy of cerebrospinal fluid TREM2 and BDNF/TrkB pathways promote mild depressive symptoms in Alzheimer's disease through tau pathology

Ze-Hu Sheng, Yuhao Chen, Yang Lü, Weihua Yu et al.
Journal of Alzheimer s Disease
Alzheimer's disease research and treatments
article

Potential synergy of cerebrospinal fluid TREM2 and BDNF/TrkB pathways promote mild depressive symptoms in Alzheimer's disease through tau pathology

Ze-Hu Sheng, Yuhao Chen, Yang Lü, Weihua Yu, Man Zhang, Fan Guo, for the Alzheimer's Disease Neuroimaging Initiative
article en

Abstract

Background Early identification of Alzheimer's disease (AD) remains challenging. Mild depressive symptoms (MDSs) during the prodromal stage accelerate cognitive decline, but the underlying mechanisms remain unclear. Neuroinflammation and neurotrophic support are implicated in cognitive impairment, yet the interaction between triggering receptor expressed on myeloid cells 2 (TREM2)-mediated neuroimmune dysregulation and brain derived neurotrophic factor (BDNF)/tropomyosin receptor kinase B (TrkB) deficits has not been established. Objective This study aimed to investigate whether alterations in cerebrospinal fluid (CSF) TREM2/sTREM2 and BDNF/TrkB interact to affect cognition in patients with AD and MDSs and whether tau pathology mediates this relationship, using observational data from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Methods ADNI data collected from 2005 to 2013 included 653 eligible participants. CSF TREM2, sTREM2, BDNF, TrkB, Aβ 42 , pTau181, and tTau levels, neuropsychiatric measures, and cognitive scores were analyzed using analysis of covariance, stratified analyses, mediation analyses, and multivariable linear regression adjusted for age, sex, education, and APOE ε4 status. Results CSF BDNF, TREM2, and sTREM2 levels varied significantly with age. sTREM2 appeared protective in early but not late disease stages. Reduced BDNF/TrkB signaling was associated with MDSs and poorer memory and executive function. Mediation analyses indicated that MDS-related cognitive impairment was partly mediated by TREM2/sTREM2-associated neuroinflammation and BDNF/TrkB dysfunction, particularly with elevated tau pathology. Conclusions TREM2-mediated neuroimmune dysfunction and impaired BDNF/TrkB support may jointly exacerbate tau-related cognitive decline in preclinical AD with MDSs. This immune-neurotrophic interaction may promote dysfunctional microglial activation, excessive inflammation, and reduced clearance, offering a potential mechanism linking depressive symptoms to accelerated AD progression and informing early risk stratification and targeted intervention.

Journal of Alzheimer s Disease
Tongji University (CN), Chongqing City Mental Health Center (CN), The Affiliated Yongchuan Hospital of Chongqing Medical University (CN), Chongqing Medical University (CN)
Alzheimer's disease research and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon